Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$2.18B+60013279.31%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steven M. Shum
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 25
- Beta
- 1.44
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -5.11
Financials
Revenue
$2.18B+60013279.3%Net Income
$888.74MEBITDA
$913.24MFree Cash Flow
$-3.02BEPS (diluted)
$0.35Shares Outstanding (diluted)
2.59M+1896.8%Operating Expenses
$1.91BCash & Debt
$3.73BReturn of Capital
$250.63MRevenue by Segment (annual)
$6.84MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.84B | $-25.13B | $-214.64 |
| 2023 | $3.02M | $-8.03M | $-5.13 |
| 2022 | $822.2K | $-10.89M | $-17.97 |
| 2021 | $4.16M | $-6.65M | $-12.52 |
| 2020 | $1.04M | $-8.35M | $-30.41 |
| 2019 | $1.48M | $-2.17M | $-8.93 |
| 2018 | $494.4K | $-3.08M | $-12.76 |
| 2017 | $282.1K | $-702.2K | $-3.16 |
| 2016 | $50.9K | $-2.12M | $-9.67 |
| 2015 | $11.7K | $-4.96M | $-23.15 |
| 2014 | $16.6K | $-1.73M | $-13.35 |
| 2013 | $27.1K | $-760.7K | $-5.86 |
| 2012 | $56.4K | $-666.5K | $-5.13 |
| 2011 | $71.5K | $-797.5K | $-6.14 |
Valuation
INVOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-69.23%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·11d ago·Neutral
INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference SARASOTA, Fla., Sept. 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, tak…
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International SARASOTA, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that Gretchen Collins, M.D.
View source ↗ - Newsbenzinga.com·49d ago·Positive
INVO Fertility Stock Surges Following Q2 Earnings Beat Shares of INVO Fertility Inc. (NASDAQ:IVF) are surging Monday afternoon after the healthcare fertility company reported second-quarter financial results that significantly outperformed Wall Street expectations on bottom-line earnings.
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Compan…
View source ↗
Earnings
Typical surprise -342.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 14$-0.62 vs $-0.14miss
- Wed, May 15$-0.42 vs $-0.16miss
- Tue, Apr 16$-4.60 vs $-0.87miss
Estimates and results for INVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INVO officers and directors.
- Bought
- $961k
- Sold
- —
25 trades
0 trades
- Shum Stevebought
- Szot Matthew Kbought
- Ryan Barbarabought
- Davis Trent Dbought
- Segal Jeffreybought
- Campbell Michael Jos.bought
- Goren Andreabought
- Messina Rebeccabought
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in INVO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.